Thumbnail Image
Publication

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Abdelhameed, Farah
; 
Kite, Chris
; 
Lagojda, Lukasz
; 
Dallaway, Alexander
; 
Chatha, Kamaljit Kaur
; 
Chaggar, Surinderjeet S.
; 
Dalamaga, Maria
; 
Kassi, Eva
; 
Kyrou, Ioannis
; 
Randeva, Harpal S.
Advisors
Editors
Other Contributors
Affiliation
University Hospitals Coventry and Warwickshire NHS Trust; University of Wolverhampton; Coventry University; University of Chester; Sowe Valley Primary Care Network; National and Kapodistrian University of Athens; Aston University; University of Derby; Agricultural University of Athens
EPub Date
Publication Date
2024-05-29
Submitted Date
Collections
Chester Medical School
Show all metadata
Files
Thumbnail Image
Article - VoR
Adobe PDF, 1.68 MB
Other Titles
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause of liver related morbidity and mortality. Currently, liver biopsy is the gold standard for assessing individuals with steatohepatitis and fibrosis. However, its invasiveness, sampling variability, and impracticality for large-scale screening has driven the search for non-invasive methods for early diagnosis and staging. In this review, we comprehensively summarise the evidence on the diagnostic performance and limitations of existing non-invasive serum biomarkers and scores in the diagnosis and evaluation of steatosis, steatohepatitis, and fibrosis. Several non-invasive serum biomarkers and scores have been developed over the last decade, although none has successfully been able to replace liver biopsy. The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metabolic dysfunction-associated steatotic liver disease (MASLD), has initiated a debate on the interchangeability of these terminologies. Indeed, there is a need for more research on the variability of the performance of non-invasive serum biomarkers and scores across the diagnostic entities of NAFLD, MAFLD and MASLD. There remains a significant need for finding valid and reliable non-invasive methods for early diagnosis and assessment of steatohepatitis and fibrosis to facilitate prompt risk stratification and management to prevent disease progression and complications. Further exploration of the landscape of MASLD under the newly defined disease subtypes is warranted, with the need for more robust evidence to support the use of commonly used serum scores against the new MASLD criteria and validation of previously developed scores. [Abstract copyright: © 2024. The Author(s).]
Citation
Abdelhameed, F., Kite, C., Lagojda, L., Dallaway, A., Chatha, K. K., Chaggar, S. S., Dalamaga, M., Kassi, E., Kyrou, I., & Randeva, H. S. (2024). Non-invasive scores and serum biomarkers for fatty liver in the era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A comprehensive review From NAFLD to MAFLD and MASLD. Current obesity Reports, 13, 510–531. https://doi.org/10.1007/s13679-024-00574-z
Publisher
Springer
Journal
Current Obesity Reports
Research Unit
URI
http://hdl.handle.net/10034/628753
DOI
10.1007/s13679-024-00574-z
PubMed ID
PubMed Central ID
Type
Article
Language
Description
The version of record of this article, first published in [Current Obesity Reports], is available online at Publisher’s website: http://dx.doi.org/10.1007/s13679-024-00574-z
Series/Report no.
ISSN
2162-4968
EISSN
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
Unfunded
Additional Links
https://link.springer.com/article/10.1007/s13679-024-00574-z